Number of patients | Median overall survival (days (95 % CI)) | Median PFS liver (days (95 % CI)) | p value (OS and PFS) | |
---|---|---|---|---|
EHD at baseline | ||||
Yes | 12 | 200 (164–236) | 83 (0–179) | 0.081 |
No | 30 | 302 (216–388) | 108 (79–137)* | 0.007 |
Metastases | ||||
Synchronous | 32 | 255 (151–359) | 92 (82–102) | 0.266 |
Metachronous | 10 | 286 (60–512) | 92 (88–96) | 0.811 |
Bevacizumab treatment | ||||
Yes | 25 | 322 (247–397) | 108 (75–141) | 0.049 |
No | 17 | 215 (180–250)* | 92 (87–97) | 0.614 |
kRAS status | ||||
Wild type | 17 | 302 (244–360) | 108 (51–165) | 0.074 |
Mutation | 9 | 166 (75–257) | 87 (0–187) | 0.05a |
Unknown | 16 | 282 (93–470) | 92 (91–93) | |
Previous liver treatment | ||||
Yes | 12 | 286 (142–430) | 86 (59–113) | 0.840 |
No | 30 | 255 (148–362) | 92 (91–94) | 0.674 |
Baseline serum level | ||||
Alkaline phosphatase | ||||
Elevated | 34 | 249 (159–339) | 274 (134–335) | 0.048 |
Normal | 8 | 355 (345–365)* | 92 (90–94)* | 0.021 |
Albumin | ||||
Decreased | 11 | 166 (94–238) | 90 (72–108) | 0.003 |
Normal | 31 | 351 (263–439)* | 92 (91–93) | 0.078 |
Treatment setting | ||||
Salvage setting | 25 | 215 (137–293) | 92 (86–98) | 0.030 |
Non-salvage setting | 17 | 358 (347–369)* | 120 (43–197) | 0.070 |
Liver response at 1 month | ||||
CR, PR or SD | 31 | 341 (224–458) | – | 0.003 |
PD | 10b | 160 (122–198)* | – | – |